Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females
Completed · Phase 4
Conditions studied: Cellulite
In brief
This is an open-label, randomized, multiple dose IIR study to evaluate the effect of Lysteda™ on bruising following QWO™ injections to the buttocks in female subjects presenting with moderate to severe cellulite. Following determination of eligibility based on inclusion/exclusion assessment, the subjects will be randomized to either Cohort A, Cohort B, or Cohort C, based on order of enrollment. Each Cohort will receive 3 Qwo™ treatments spaced 21 days apart, with 1300 mg of Lysteda™ TID PO at one, two, or all three treatments of Qwo™. Cohort A will be given tranexamic acid at the first treatment, Cohort B at the first and second treatment, and Cohort C at all three treatments. All buttock CCH injections will follow the on-label injection protocol. Subjects will participate in the study for 65 days total, with an additional screening period of 14 days. There will be a total of 11 visits (Screening, Day 1, Day 4, Day 14, Day 22, Day 26, Day 36, Day 43, Day 47, Day 57, Day 65).
Key facts
- Study ID
- NCT05309525
- Run by
- Luxurgery
- People needed
- 17
- Starts
- 2022-04-22
- Expected to finish
- 2022-10-01
- Last updated by the study team
- 2023-03-08
Who can join
Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.
Where it is running
- Luxurgery — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.